Abstract:The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf. Elevation of these up-stream signals occurs frequently in a variety of malignancies and ERK kinases play critical roles in promoting cell proliferation. Therefore, inhibition of MEK-mediated ERK activation is very appealing in cancer therapy. Consequently, numerous MEK inhibitors have been developed over the years. However, clinical trials have yet to produce overwhelming support for using MEK inhibitors in cancer therapy. Although complex reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy. Recent developments may support this alternative possibility. Accumulating evidence now demonstrated that the MEK-ERK pathway contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. During DDR, the MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division. Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation. As a result, cells may continue to proliferate in the presence of DNA lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. Alternatively, reduction in checkpoint activation may prevent efficient repair of DNA damages, which may cause apoptosis or cell catastrophe, thereby enhancing chemotherapy's efficacy. This review summarizes our current understanding of the participation of the ERK kinases in DDR.

Regulation of ERK Signaling Pathway in Biological Behaviors of Tumor Cells

ERK/MAPK signalling pathway and tumorigenesis

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

The MAPK Signalling Pathways and Colorectal Cancer

Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

ERK signalling: a master regulator of cell behaviour, life and fate

ERK MAP kinase in G1 cell cycle progression and cancer

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

Role of the Atypical MAPK ERK3 in Cancer Growth and Progression

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

MAPK Signaling in Inflammation-Associated Cancer Development

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Dynamic model and regulatory mechanism of integrated ERK signal pathway activated by epidermal growth factor

New Tumor Suppressor Cxxc Finger Protein 4 Inactivates Mitogen Activated Protein Kinase Signaling

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers

Bidirectional Signals Transduced by TOPK-ERK Interaction Increase Tumorigenesis of HCT116 Colorectal Cancer Cells

ERK1/2 MAP Kinases in Cell Survival and Apoptosis

ERK in Learning and Memory: A Review of Recent Research